Supplements

Transvenous phrenic nerve stimulation improves apnoea indices, oxygenation, and quality of life in adults with central sleep apnoea, including those with heart failure.

The 2025 American Academy of Sleep Medicine Clinical Practice Guideline recognizes transvenous phrenic nerve stimulation as an evidence-based therapy for central sleep apnoea in adults, including heart failure patients. Current evidence indicates improvements in apnoea indices, oxygenation, and quality of life, though effects on mortality and hospitalisation require further prospective randomized data.

Last updated: Aug 14, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. The 2025 American Academy of Sleep Medicine Central Sleep Apnoea Guidelines and the Heart Failure Patient.

observational

Kaplan SM, Berry RB, Abraham WT · Cardiac failure review (2026)

Participants: N/A
Duration: N/A
Intervention: Transvenous phrenic nerve stimulation
Outcome: Apnoea indices, oxygenation, quality of life, mortality, hospitalisation
Effect Size: N/A
Population: Adults with central sleep apnoea, including those with heart failure

Result:

PubMed: 42582605DOI: 10.15420/cfr.2025.60

Mechanism Graph

Central sleep apnoea arises from instability in respiratory control, often associated with heart failure.
↓
Transvenous phrenic nerve stimulation activates the diaphragm, restoring regular breathing patterns.
↓
Improved ventilation reduces apnoea-hypopnoea events and improves oxygenation.
↓
Result: Improved quality of life and reduced symptoms.

Limitations

  • ⚠Effect on mortality and hospitalisation lacks prospective randomized data.
  • ⚠Identification of patients with central sleep apnoea is often missed in clinical practice.

Frequently Asked Questions

What is transvenous phrenic nerve stimulation?▼

It is a therapy that uses a device to stimulate the phrenic nerve, causing the diaphragm to contract and restore normal breathing during sleep.

Is this therapy approved for heart failure patients with central sleep apnoea?▼

Yes, the 2025 AASM guideline recognizes it as an evidence-based therapy for adults with CSA, including those with heart failure.

What outcomes improve with this therapy?▼

Apnoea indices, oxygenation, and quality of life improve, but mortality and hospitalisation benefits are not yet confirmed.

Why is central sleep apnoea often missed in heart failure patients?▼

Symptoms may be attributed to heart failure itself, and routine screening for CSA is not always performed.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Kaplan SM, Berry RB, Abraham WT. "The 2025 American Academy of Sleep Medicine Central Sleep Apnoea Guidelines and the Heart Failure Patient.." Cardiac failure review, 2026. PMID: 42582605 DOI: 10.15420/cfr.2025.60
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.